Our recent U.S. FDA & European Medicines Agency (EMA) submissions reflect our commitment to early intervention for adults with high-risk smoldering #MultipleMyeloma, aiming to intercept the disease earlier: t.co/dLTCsR7Y57 #JNJOncology t.co/fHEudSCErp